Loading…

Control of cancer stem cell like population by intracellular target identification followed by the treatment with peptide-siRNA complex

Cancer stem cells (CSCs) are a subpopulation of cancer cells and have been known to create cancer reoccurrence during cancer therapy due to their stem cell-like characteristics. However, exact target to control the CSC has not been fully established. Here, we enriched CD44High population of MDA-MB-2...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical and biophysical research communications 2017-09, Vol.491 (3), p.827-833
Main Authors: Suh, Jin Sook, Lee, Hyun Jung, Nam, Hyun, Jo, Beom Soo, Lee, Dong Woo, Kim, Ji-Hye, Lee, Jue Yeon, Chung, Chong Pyoung, Lee, Gene, Park, Yoon Jeong
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c356t-4d1dd715529289f8c1d6e95317c49876643021a9a469b2e245c85cfa3f5018013
cites cdi_FETCH-LOGICAL-c356t-4d1dd715529289f8c1d6e95317c49876643021a9a469b2e245c85cfa3f5018013
container_end_page 833
container_issue 3
container_start_page 827
container_title Biochemical and biophysical research communications
container_volume 491
creator Suh, Jin Sook
Lee, Hyun Jung
Nam, Hyun
Jo, Beom Soo
Lee, Dong Woo
Kim, Ji-Hye
Lee, Jue Yeon
Chung, Chong Pyoung
Lee, Gene
Park, Yoon Jeong
description Cancer stem cells (CSCs) are a subpopulation of cancer cells and have been known to create cancer reoccurrence during cancer therapy due to their stem cell-like characteristics. However, exact target to control the CSC has not been fully established. Here, we enriched CD44High population of MDA-MB-231 cells by CD44 antibody as a CSC marker. By Phospho Antibody Array, CD44High population of MDA-MB-231 cells reveals Feline sarcoma-related tyrosine kinase (FER) protein was highly activated. When FER siRNA and low molecular weight protamine (LMWP) as cell penetrating peptides are applied to this population, cancer migration and colony forming ability are inhibited. Moreover, silencing FER using FER siRNA and LMWP conjugates enhances anti-metastasis related factors including E-cadherin, p75 and p63. Taken together, FER is a new marker for targeting breast CSCs and peptide-mediated siRNA method could be an effective and safe way of delivery and be a new therapeutic strategy for targeting breast cancer. •FER protein is highly activated in the cancer stem cells derived from human breast tumors.•Silencing FER by siRNA reduces stemness and metastatic features of cancer stem cells.•FER siRNA complex with the cell-penetrating peptide showed more effective and less toxic method.
doi_str_mv 10.1016/j.bbrc.2017.05.148
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1903943740</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006291X17310483</els_id><sourcerecordid>1903943740</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-4d1dd715529289f8c1d6e95317c49876643021a9a469b2e245c85cfa3f5018013</originalsourceid><addsrcrecordid>eNp9kUFv1DAQhS0EotvCH-CAfOSSMHbsJJa4VKtCkSqQEEjcLMeZUC9OHGwvpb-Av42jLRw5jTTzvSe9eYS8YFAzYO3rQz0M0dYcWFeDrJnoH5EdAwUVZyAekx0AtBVX7OsZOU_pAMCYaNVTcsZ7KUUvxI783oclx-BpmKg1i8VIU8aZWvSeevcd6RrWozfZhYUO99QV2mzHsos0m_gNM3UjLtlNzp6wKXgf7nDc-HyLNEc0eS4IvXP5lq645qKokvv04ZLaMK8efz0jTybjEz5_mBfky9urz_vr6ubju_f7y5vKNrLNlRjZOHZMSq54r6besrFFJRvWWaH6rm1FA5wZZUrOgSMX0vbSTqaZJLAeWHNBXp181xh-HDFlPbu05TELhmPSTEGjRNMJKCg_oTaGlCJOeo1uNvFeM9BbAfqgtwL0VoAGqUsBRfTywf84zDj-k_z9eAHenAAsKX86jDpZh-Xxo4tosx6D-5__HxeDmKg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1903943740</pqid></control><display><type>article</type><title>Control of cancer stem cell like population by intracellular target identification followed by the treatment with peptide-siRNA complex</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Suh, Jin Sook ; Lee, Hyun Jung ; Nam, Hyun ; Jo, Beom Soo ; Lee, Dong Woo ; Kim, Ji-Hye ; Lee, Jue Yeon ; Chung, Chong Pyoung ; Lee, Gene ; Park, Yoon Jeong</creator><creatorcontrib>Suh, Jin Sook ; Lee, Hyun Jung ; Nam, Hyun ; Jo, Beom Soo ; Lee, Dong Woo ; Kim, Ji-Hye ; Lee, Jue Yeon ; Chung, Chong Pyoung ; Lee, Gene ; Park, Yoon Jeong</creatorcontrib><description>Cancer stem cells (CSCs) are a subpopulation of cancer cells and have been known to create cancer reoccurrence during cancer therapy due to their stem cell-like characteristics. However, exact target to control the CSC has not been fully established. Here, we enriched CD44High population of MDA-MB-231 cells by CD44 antibody as a CSC marker. By Phospho Antibody Array, CD44High population of MDA-MB-231 cells reveals Feline sarcoma-related tyrosine kinase (FER) protein was highly activated. When FER siRNA and low molecular weight protamine (LMWP) as cell penetrating peptides are applied to this population, cancer migration and colony forming ability are inhibited. Moreover, silencing FER using FER siRNA and LMWP conjugates enhances anti-metastasis related factors including E-cadherin, p75 and p63. Taken together, FER is a new marker for targeting breast CSCs and peptide-mediated siRNA method could be an effective and safe way of delivery and be a new therapeutic strategy for targeting breast cancer. •FER protein is highly activated in the cancer stem cells derived from human breast tumors.•Silencing FER by siRNA reduces stemness and metastatic features of cancer stem cells.•FER siRNA complex with the cell-penetrating peptide showed more effective and less toxic method.</description><identifier>ISSN: 0006-291X</identifier><identifier>EISSN: 1090-2104</identifier><identifier>DOI: 10.1016/j.bbrc.2017.05.148</identifier><identifier>PMID: 28554844</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Apoptosis - drug effects ; Apoptosis - genetics ; Cell Line, Tumor ; Cell penetrating peptide ; Epithelial-to-mesenchymal transition ; FER siRNA delivery ; FER tyrosine kinase ; Gene Silencing ; Gene Targeting - methods ; Genetic Therapy - methods ; Human breast cancer stem cells ; Humans ; Molecular Targeted Therapy - methods ; Neoplastic Stem Cells - drug effects ; Neoplastic Stem Cells - physiology ; Peptides - administration &amp; dosage ; Peptides - pharmacokinetics ; Pluripotency ; Protein-Tyrosine Kinases - antagonists &amp; inhibitors ; Protein-Tyrosine Kinases - genetics ; RNA, Small Interfering - genetics ; RNA, Small Interfering - therapeutic use ; Treatment Outcome</subject><ispartof>Biochemical and biophysical research communications, 2017-09, Vol.491 (3), p.827-833</ispartof><rights>2017</rights><rights>Copyright © 2017. Published by Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-4d1dd715529289f8c1d6e95317c49876643021a9a469b2e245c85cfa3f5018013</citedby><cites>FETCH-LOGICAL-c356t-4d1dd715529289f8c1d6e95317c49876643021a9a469b2e245c85cfa3f5018013</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28554844$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Suh, Jin Sook</creatorcontrib><creatorcontrib>Lee, Hyun Jung</creatorcontrib><creatorcontrib>Nam, Hyun</creatorcontrib><creatorcontrib>Jo, Beom Soo</creatorcontrib><creatorcontrib>Lee, Dong Woo</creatorcontrib><creatorcontrib>Kim, Ji-Hye</creatorcontrib><creatorcontrib>Lee, Jue Yeon</creatorcontrib><creatorcontrib>Chung, Chong Pyoung</creatorcontrib><creatorcontrib>Lee, Gene</creatorcontrib><creatorcontrib>Park, Yoon Jeong</creatorcontrib><title>Control of cancer stem cell like population by intracellular target identification followed by the treatment with peptide-siRNA complex</title><title>Biochemical and biophysical research communications</title><addtitle>Biochem Biophys Res Commun</addtitle><description>Cancer stem cells (CSCs) are a subpopulation of cancer cells and have been known to create cancer reoccurrence during cancer therapy due to their stem cell-like characteristics. However, exact target to control the CSC has not been fully established. Here, we enriched CD44High population of MDA-MB-231 cells by CD44 antibody as a CSC marker. By Phospho Antibody Array, CD44High population of MDA-MB-231 cells reveals Feline sarcoma-related tyrosine kinase (FER) protein was highly activated. When FER siRNA and low molecular weight protamine (LMWP) as cell penetrating peptides are applied to this population, cancer migration and colony forming ability are inhibited. Moreover, silencing FER using FER siRNA and LMWP conjugates enhances anti-metastasis related factors including E-cadherin, p75 and p63. Taken together, FER is a new marker for targeting breast CSCs and peptide-mediated siRNA method could be an effective and safe way of delivery and be a new therapeutic strategy for targeting breast cancer. •FER protein is highly activated in the cancer stem cells derived from human breast tumors.•Silencing FER by siRNA reduces stemness and metastatic features of cancer stem cells.•FER siRNA complex with the cell-penetrating peptide showed more effective and less toxic method.</description><subject>Apoptosis - drug effects</subject><subject>Apoptosis - genetics</subject><subject>Cell Line, Tumor</subject><subject>Cell penetrating peptide</subject><subject>Epithelial-to-mesenchymal transition</subject><subject>FER siRNA delivery</subject><subject>FER tyrosine kinase</subject><subject>Gene Silencing</subject><subject>Gene Targeting - methods</subject><subject>Genetic Therapy - methods</subject><subject>Human breast cancer stem cells</subject><subject>Humans</subject><subject>Molecular Targeted Therapy - methods</subject><subject>Neoplastic Stem Cells - drug effects</subject><subject>Neoplastic Stem Cells - physiology</subject><subject>Peptides - administration &amp; dosage</subject><subject>Peptides - pharmacokinetics</subject><subject>Pluripotency</subject><subject>Protein-Tyrosine Kinases - antagonists &amp; inhibitors</subject><subject>Protein-Tyrosine Kinases - genetics</subject><subject>RNA, Small Interfering - genetics</subject><subject>RNA, Small Interfering - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0006-291X</issn><issn>1090-2104</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kUFv1DAQhS0EotvCH-CAfOSSMHbsJJa4VKtCkSqQEEjcLMeZUC9OHGwvpb-Av42jLRw5jTTzvSe9eYS8YFAzYO3rQz0M0dYcWFeDrJnoH5EdAwUVZyAekx0AtBVX7OsZOU_pAMCYaNVTcsZ7KUUvxI783oclx-BpmKg1i8VIU8aZWvSeevcd6RrWozfZhYUO99QV2mzHsos0m_gNM3UjLtlNzp6wKXgf7nDc-HyLNEc0eS4IvXP5lq645qKokvv04ZLaMK8efz0jTybjEz5_mBfky9urz_vr6ubju_f7y5vKNrLNlRjZOHZMSq54r6besrFFJRvWWaH6rm1FA5wZZUrOgSMX0vbSTqaZJLAeWHNBXp181xh-HDFlPbu05TELhmPSTEGjRNMJKCg_oTaGlCJOeo1uNvFeM9BbAfqgtwL0VoAGqUsBRfTywf84zDj-k_z9eAHenAAsKX86jDpZh-Xxo4tosx6D-5__HxeDmKg</recordid><startdate>20170923</startdate><enddate>20170923</enddate><creator>Suh, Jin Sook</creator><creator>Lee, Hyun Jung</creator><creator>Nam, Hyun</creator><creator>Jo, Beom Soo</creator><creator>Lee, Dong Woo</creator><creator>Kim, Ji-Hye</creator><creator>Lee, Jue Yeon</creator><creator>Chung, Chong Pyoung</creator><creator>Lee, Gene</creator><creator>Park, Yoon Jeong</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20170923</creationdate><title>Control of cancer stem cell like population by intracellular target identification followed by the treatment with peptide-siRNA complex</title><author>Suh, Jin Sook ; Lee, Hyun Jung ; Nam, Hyun ; Jo, Beom Soo ; Lee, Dong Woo ; Kim, Ji-Hye ; Lee, Jue Yeon ; Chung, Chong Pyoung ; Lee, Gene ; Park, Yoon Jeong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-4d1dd715529289f8c1d6e95317c49876643021a9a469b2e245c85cfa3f5018013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Apoptosis - drug effects</topic><topic>Apoptosis - genetics</topic><topic>Cell Line, Tumor</topic><topic>Cell penetrating peptide</topic><topic>Epithelial-to-mesenchymal transition</topic><topic>FER siRNA delivery</topic><topic>FER tyrosine kinase</topic><topic>Gene Silencing</topic><topic>Gene Targeting - methods</topic><topic>Genetic Therapy - methods</topic><topic>Human breast cancer stem cells</topic><topic>Humans</topic><topic>Molecular Targeted Therapy - methods</topic><topic>Neoplastic Stem Cells - drug effects</topic><topic>Neoplastic Stem Cells - physiology</topic><topic>Peptides - administration &amp; dosage</topic><topic>Peptides - pharmacokinetics</topic><topic>Pluripotency</topic><topic>Protein-Tyrosine Kinases - antagonists &amp; inhibitors</topic><topic>Protein-Tyrosine Kinases - genetics</topic><topic>RNA, Small Interfering - genetics</topic><topic>RNA, Small Interfering - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suh, Jin Sook</creatorcontrib><creatorcontrib>Lee, Hyun Jung</creatorcontrib><creatorcontrib>Nam, Hyun</creatorcontrib><creatorcontrib>Jo, Beom Soo</creatorcontrib><creatorcontrib>Lee, Dong Woo</creatorcontrib><creatorcontrib>Kim, Ji-Hye</creatorcontrib><creatorcontrib>Lee, Jue Yeon</creatorcontrib><creatorcontrib>Chung, Chong Pyoung</creatorcontrib><creatorcontrib>Lee, Gene</creatorcontrib><creatorcontrib>Park, Yoon Jeong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Biochemical and biophysical research communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suh, Jin Sook</au><au>Lee, Hyun Jung</au><au>Nam, Hyun</au><au>Jo, Beom Soo</au><au>Lee, Dong Woo</au><au>Kim, Ji-Hye</au><au>Lee, Jue Yeon</au><au>Chung, Chong Pyoung</au><au>Lee, Gene</au><au>Park, Yoon Jeong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Control of cancer stem cell like population by intracellular target identification followed by the treatment with peptide-siRNA complex</atitle><jtitle>Biochemical and biophysical research communications</jtitle><addtitle>Biochem Biophys Res Commun</addtitle><date>2017-09-23</date><risdate>2017</risdate><volume>491</volume><issue>3</issue><spage>827</spage><epage>833</epage><pages>827-833</pages><issn>0006-291X</issn><eissn>1090-2104</eissn><abstract>Cancer stem cells (CSCs) are a subpopulation of cancer cells and have been known to create cancer reoccurrence during cancer therapy due to their stem cell-like characteristics. However, exact target to control the CSC has not been fully established. Here, we enriched CD44High population of MDA-MB-231 cells by CD44 antibody as a CSC marker. By Phospho Antibody Array, CD44High population of MDA-MB-231 cells reveals Feline sarcoma-related tyrosine kinase (FER) protein was highly activated. When FER siRNA and low molecular weight protamine (LMWP) as cell penetrating peptides are applied to this population, cancer migration and colony forming ability are inhibited. Moreover, silencing FER using FER siRNA and LMWP conjugates enhances anti-metastasis related factors including E-cadherin, p75 and p63. Taken together, FER is a new marker for targeting breast CSCs and peptide-mediated siRNA method could be an effective and safe way of delivery and be a new therapeutic strategy for targeting breast cancer. •FER protein is highly activated in the cancer stem cells derived from human breast tumors.•Silencing FER by siRNA reduces stemness and metastatic features of cancer stem cells.•FER siRNA complex with the cell-penetrating peptide showed more effective and less toxic method.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28554844</pmid><doi>10.1016/j.bbrc.2017.05.148</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0006-291X
ispartof Biochemical and biophysical research communications, 2017-09, Vol.491 (3), p.827-833
issn 0006-291X
1090-2104
language eng
recordid cdi_proquest_miscellaneous_1903943740
source ScienceDirect Freedom Collection 2022-2024
subjects Apoptosis - drug effects
Apoptosis - genetics
Cell Line, Tumor
Cell penetrating peptide
Epithelial-to-mesenchymal transition
FER siRNA delivery
FER tyrosine kinase
Gene Silencing
Gene Targeting - methods
Genetic Therapy - methods
Human breast cancer stem cells
Humans
Molecular Targeted Therapy - methods
Neoplastic Stem Cells - drug effects
Neoplastic Stem Cells - physiology
Peptides - administration & dosage
Peptides - pharmacokinetics
Pluripotency
Protein-Tyrosine Kinases - antagonists & inhibitors
Protein-Tyrosine Kinases - genetics
RNA, Small Interfering - genetics
RNA, Small Interfering - therapeutic use
Treatment Outcome
title Control of cancer stem cell like population by intracellular target identification followed by the treatment with peptide-siRNA complex
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T03%3A51%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Control%20of%20cancer%20stem%20cell%20like%20population%20by%20intracellular%20target%20identification%20followed%20by%20the%20treatment%20with%20peptide-siRNA%20complex&rft.jtitle=Biochemical%20and%20biophysical%20research%20communications&rft.au=Suh,%20Jin%20Sook&rft.date=2017-09-23&rft.volume=491&rft.issue=3&rft.spage=827&rft.epage=833&rft.pages=827-833&rft.issn=0006-291X&rft.eissn=1090-2104&rft_id=info:doi/10.1016/j.bbrc.2017.05.148&rft_dat=%3Cproquest_cross%3E1903943740%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c356t-4d1dd715529289f8c1d6e95317c49876643021a9a469b2e245c85cfa3f5018013%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1903943740&rft_id=info:pmid/28554844&rfr_iscdi=true